Background An increasing number of studies have reported ethnic differences in sunitinib
INTRODUCTION
ethnic differences in drug response in the field of oncology are known. Ye et al. 6 compared sorafenib outcomes between Chinese and Caucasian RCC patients. Sorafenib appeared to be more effective in patients of Chinese ethnicity than in Caucasian patients. However, Chinese patients more frequently experienced hand-foot syndrome. Similarly, ethnic differences in the frequency of axitinib-related hand-foot syndrome were found between Japanese and Caucasian patients. 7 Until now, differences in sunitinib outcomes among ethnicities have been investigated in two studies. In 2013, Motzer et al. 8 retrospectively collected data from six clinical trials and reported that there was no significant difference in survival in Caucasian (n=884) vs Asian mRCC patients (n=70). However, several sunitinib-induced adverse events such as handfoot syndrome occurred significantly more often in Asian patients compared to Caucasian patients (70% vs. 28%, P<0.001). In addition, evidence from a global expanded access program (EAP) with 4,371 mRCC patients reported a comparable sunitinib efficacy between Asian (n=325) and non-Asian patients (n=4,046), and major differences in the incidence of all grade stomatitis (39% vs 26%, Asian and non-Asian patients, respectively), hand-foot syndrome (39% vs 23%), asthenia (12% vs 22%), and skin discoloration (25% vs 9%). 9 Recently, a prospective, post-marketing study, including 1,689 Japanese patients with mRCC, was performed to investigate sunitinib efficacy and toxicity in real-world clinical practice. Hand-foot syndrome as well as thrombocytopenia were observed at higher frequencies and with greater severity in Japanese as compared with Caucasian patients. 10 Although several studies investigated ethnic differences in sunitinib efficacy and toxicity, no comprehensive analysis is available at present. Therefore, we systematically collected available published data and performed a meta-analysis to compare sunitinib efficacy as well as toxicity in Asian and Caucasian mRCC patients.
MATERIAL AND METHODS

Systematic literature search strategy and selection process
A systematic search for publications archived in MEDLINE, EMBASE and Web of Science prior to October 9, 2015 was conducted. A search syntax was compiled by combining "renal cell carcinoma" AND "sunitinib" AND "ethnicity". Various synonyms and related terms for all subjects were used. Duplicate articles were removed after manual curation. Initially, articles were scanned by title and by abstract. Meeting abstracts, case reports, reviews and meta-analyses were excluded. Reference lists were carefully evaluated to identify additional relevant papers. Only full-text articles published in English, reporting on efficacy and toxicity in single sunitinib treatment were included. The treatment had to consist of an initial regimen of 50mg daily dose (4-week on/2-week off) or continuous 37.5 daily regimen in mRCC patients.
Endpoints and data extraction
The primary endpoints of this meta-analysis were progression-free survival (PFS), 
Statistical analysis
Meta-analysis was performed based on the survival outcomes coming from the included studies. Individual patient data were reconstructed from the estimated PFS and OS probabilities. Data in each study consisted of PFS or OS and probabilities every 5 months for the first 2 or 3 years after treatment. Details concerning the reconstruction of the data were described in the Appendix (Supplementary document 1) . Further technical details were discussed in Fiocco et al. 12, 13 A multivariate random-effects model for a joint analysis of survival proportions reported at different times in the individual studies was used to combine all available information in each article included in the meta-analysis on the endpoint of PFS and OS. Moreover, a series of separate meta-analysis on toxicity data were performed for Caucasian and Asian patients as well. A random effect model was used to pool specific proportion in order to estimate an overall proportion and its associated confidence intervals. Inverse variance method which gives more weight to larger trials was used to pool outcomes for different studies. 14 All statistical analyses were performed in R environments version 2.18 (http://cran.rproject.org/).
RESULTS
Search results
Our systematic search identified 1,514 publications. Flowchart of study selection. The original search on the 9 October 2015 resulted in a total of 1514 publications. Three additional publications were included based on manual curation of reference lists. In total 1484 publications were excluded due to duplication (n=580), title and abstract (n=547), data were not from single sunitinib treatment or included patients with multiple tumor types (n=349), dosing regimen was not 50 mg 4/2 schedule or continuous 37,5 mg daily (n=2), duplicate cohort (n=3), only elderly or renal insufficient or sunitinib treatment more than 1 year patients were included (n=3). Finally, 33 publications were included in our paper. 
Meta-analysis of sunitinib outcomes between Caucasian and Asian mRCC patients
The results of the meta-analysis for all grade toxicities in Asian and Caucasian mRCC patients were displayed in Figure 2 . The incidence of hand-foot syndrome in Asian patients (52%, 95%CI: 45%-60%) was found to be two times higher than that in Caucasian patients (24%, 95%CI: 19%-29%). Asian and Caucasian patients had a similar incidence of toxicity other than hand-foot syndrome.
Figure 2
Pooled incidence of all grade toxicities Pooled incidence of toxicities higher than grade 2 was shown in Figure 3 . Asian patients showed a higher percentage of > grade 2 fatigue, hand-foot syndrome and thrombocytopenia of 17 (95% CI: 11-13)%, 13 (95% CI: 9-17)% and 25 (95% CI: 18-32)%, in comparison to Caucasian patients for whom the results were 8 (95% CI: 6-9)%, 5 (95% CI: 3-7)% and 6 (95% CI: 2-10)%, respectively. There were no significant differences of other > grade 2 toxicities. 
DISCUSSION
In the current meta-analysis, we systematically collected available data to compare sunitinib outcomes between Asian and Caucasian mRCC patients. Our results showed that the efficacy of sunitinib in mRCC patients from Caucasian and Asian origin was similar.
However, a higher incidence of all grades hand-foot syndrome, > grade 2 fatigue, > grade 2 hand-foot syndrome and > grade 2 thrombocytopenia was observed in Asian patients. In addition, we compared the ORR among three patient settings. The range of ORR of patients from real-world clinical practice appeared to be larger than that from the clinical trial setting. However, the difference of ORR is not as large as we had expected, because the patients from real-world clinical practice usually were more heterogeneous than those enrolled in a clinical trial.
A potential explanation for the observed higher risk of toxicity in Asian patients may be and SU12662 in Asian patients were about 15% higher compared to other ethnical groups.
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In addition, Nagata et al. 45 reported that the total trough level of sunitinib in 6 Japanese RCC patients using 50mg daily 4/2 schedule was higher than 100 ng/mL, whereas the average concentration of total sunitinib in Caucasian male patients (body weight: 77kg, 50mg daily dose) stated by Houk et al. 44 was 30-90 ng/mL. Of note, in the studies included in our meta-analysis, sunitinib was administrated as a standard daily dose of 50mg in a 4-week on/2-week off schedule. Compared to the Caucasian population, Asian people in general have a relatively lower body surface area (BSA), and as a result drug exposure in Asian patients may be higher after a standard dose. However, no or only a relatively small effect of BSA on sunitinib pharmacokinetics was identified in both Caucasian 44 and Japanese patients. 46 In contrast, the lean body mass (LBM) has recently been identified to be related with sunitinib and SU12662 exposure in 92 patients with solid tumors. The authors reported that patients with a lower LBM had a higher sunitinib and SU12662 Moreover, a recent retrospective study in 114 Caucasian patients with sunitinib treatment showed that CYP3A4*22 (rs35599367 C>T) was associated with decreased sunitinib clearance. 55 It has been reported that activity of CYP3A4 enzyme is particularly sensitive to dietary effects. 57 Although the potential effect of food on sunitinib pharmacokinetics was not supported by the phase I study in healthy subjects, in which no difference of sunitinib and SU12662 pharmacokinetics was found between patients with single dose of sunitinib after either 10-h fast or a high-fat meal, the effect of long-term cooking habit, such as the frequently used CYP3A4-inhibiting spices, 58 could not be ignored. 9 It was shown that Asian-O patients had lower incidence of toxicity compared to Asian-A, but had a similar incidence of toxicity as non-Asian patients. This observation points towards the direction of diet and body weight being a major determinant of sunitinib toxicity. Indeed, Park et al.
reported that Asians living in the US have a comparable amount of visceral fat to that of European Americans. 59 Moreover, a meta-analysis showed that visceral fat in Japanese population was significantly lower than that in Caucasians. 60 Obviously, visceral fat may modify drug distribution and thus decrease drug exposure in tumor. 61 In a real world clinical setting, reimbursement policies in different countries may indirectly contribute to ethnic differences of sunitinib efficacy and toxicity. For example, even though five agents (sorafenib, sunitinib, everolimus, interferon-alpha and interleukin-2) are currently approved by Chinese Food and Drug Administration for mRCC treatment, reimbursement is only available for interferon-alpha and interleukin-2. 62 This may imply that sunitinib is more frequently used as a second-line treatment of advanced disease patients in some Asian countries compared to Caucasian countries. However, this potential effect does not play a role in our meta-analysis, as no differences in the percentage of patients with prior treatment from Asian or Caucasian countries was observed (Supplementary Table 1 ).
The present meta-analysis pooled all available data from three different patient settings (clinical trial, EAP and real-world clinical practice). Due to the strict and homogeneous patient selection criteria, drug effects in clinical trials may not be fully representative of real-world clinical practice and data from various types of drugs suggest the existence of a "trial effect". 63 Patients from EAP were those who were not eligible to participate in clinical trials due to exclusion criteria or were from countries where regulatory approval
had not yet been granted. Therefore, the results from EAP may better reflect, to some extent, the results found in real-world clinical practice. Subgroup analyses could give some insight into inter-setting differences of sunitinib efficacy and toxicity between ethnicities, but the data available at present do not allow for performing such subgroup analysis. However, the comparison of sunitinib efficacy between clinical trial participants and a matched cohort of non-participants was explored by Keizman D et al, but no significant difference was observed . 63 Available data indicate that Asian patients more frequently need a toxicity-related dose reduction or discontinuation compared to Caucasian patients with 35%-76% vs. 24%-32%, respectively. 20 It has been suggested that Asian patients should start their treatment with a lower initial sunitinib dose. This approach was evaluated in a prospective study comparing the conventional dose regimen (50mg daily, 4-week on/2-week off) with an attenuated dose regimen (37.5mg daily, 4-week on/2-week off) in 160 Singapore mRCC patients. The results show that patients with attenuated dose regimen had comparable PFS and OS, but had significantly lower incidence of toxicity compared to those with conventional dose regimen. From this study, it seems that Asian patients, with a reduced initial dose, have reached a balance of minimum toxicity and maximum efficacy. 20 The authors would like to point out that this study has some limitations that ought to be considered. There is a lack of standard definition of Asian and Caucasian origin, and it is difficult to designate a multiracial identity. Indeed, the majority of included publications did not report detailed information of ethnicity. Even though we contacted the authors of included studies, no full ethnic data appeared to be available. Therefore, we decided to regard the patients enrolled in Asian countries as Asian and patients enrolled in European and American studies as Caucasian, except when the ethnic data were presented otherwise.
Moreover, while sunitinib is a standard-of-care treatment in clear cell RCC, it is acknowledged that efficacy is dependent of histological tumor type. 64 
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This assumes that the censored observations are distributed uniformly over the interval.
Under the same assumption, from the number of patients at risk r j , we can define the number of person-years over interval I j , as r j = Δ j (r j -c j /2), where Δ j = t j -t j-1 is the length of I j . Following the methodology described, the number of patients at risk, the number of deaths and the number of censored patients during the time intervals for each study involved in the meta-analysis have been reconstructed. A Poisson mixed model with study as random effects has been fitted to the reconstructed data, to estimate the pooled PFS and OS probability. 
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